Annalisa Petrelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Annalisa Petrelli has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Silvia Giordano
Department of Oncology, University of Torino, 10124 Torino, Italy
4 shared publications A. Columbano
3 shared publicationsA. Perra
3 shared publications- Giovanna M. Ledda-Columbano
Department of Toxicology, Oncology and Molecular Pathology Unit, University of Cagliari, Italy
3 shared publications S. Giordano
3 shared publicationsAlessandro Giammona
Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory, University of Palermo, Palermo, Italy
2 shared publications
Latest Publications
- Open Access
- 13 August 2019
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (48) , 5003-5004
Correction: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy
[This corrects the article DOI: 10.18632/oncotarget.2962.].
- 13 August 2019
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (48) , 5003-5004
Open AccessCorrection: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy
[This corrects the article DOI: 10.18632/oncotarget.2962.].
- 1 April 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 62, S428
P0317 : Down-regulation of Hao2 is associated with the onset and development of hepatocellular carcinoma in rodents
- 1 April 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 62, S428
P0317 : Down-regulation of Hao2 is associated with the onset and development of hepatocellular carcinoma in rodents
- 1 April 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 62, S462
P0397 : Nrf2 mutations are an early and frequent event in the development of rat hepatocellular carcinoma
- 1 April 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 62, S462
P0397 : Nrf2 mutations are an early and frequent event in the development of rat hepatocellular carcinoma
- Open Access
- 11 December 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (4) , 2315-2330
By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy
Basal-like breast cancer is an aggressive tumor subtype with a poor response to conventional therapies. Tumor formation and relapse are sustained by a cell subset of Breast Cancer Stem Cells (BrCSCs). Here we show that miR-100 inhibits maintenance and expansion of BrCSCs in basal-like cancer through Polo-like kinase1 (Plk1) down-regulation. Moreover, miR-100 favors BrCSC differentiation, converting a basal like phenotype into luminal. It induces the expression of a functional estrogen receptor (ER) and renders basal-like BrCSCs responsive to hormonal therapy. The key role played by miR-100 in breast cancer free-survival is confirmed by the analysis of a cohort of patients’ tumors, which shows that low expression of miR-100 is a negative prognostic factor and is associated with gene signatures of high grade undifferentiated tumors. Our findings indicate a new possible therapeutic strategy, which could make aggressive breast cancers responsive to standard treatments.
- 11 December 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (4) , 2315-2330
Open AccessBy promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy
Basal-like breast cancer is an aggressive tumor subtype with a poor response to conventional therapies. Tumor formation and relapse are sustained by a cell subset of Breast Cancer Stem Cells (BrCSCs). Here we show that miR-100 inhibits maintenance and expansion of BrCSCs in basal-like cancer through Polo-like kinase1 (Plk1) down-regulation. Moreover, miR-100 favors BrCSC differentiation, converting a basal like phenotype into luminal. It induces the expression of a functional estrogen receptor (ER) and renders basal-like BrCSCs responsive to hormonal therapy. The key role played by miR-100 in breast cancer free-survival is confirmed by the analysis of a cohort of patients’ tumors, which shows that low expression of miR-100 is a negative prognostic factor and is associated with gene signatures of high grade undifferentiated tumors. Our findings indicate a new possible therapeutic strategy, which could make aggressive breast cancers responsive to standard treatments.
- 17 February 2012
- Published by Wiley
- p. 149-165
Polypharmacological Kinase Inhibitors: New Hopes for Cancer Therapy
- 17 February 2012
- Published by Wiley
- p. 149-165
Polypharmacological Kinase Inhibitors: New Hopes for Cancer Therapy
- 16 January 2012
- Published by Springer Nature in Oncogene
- Vol. 31 (42) , 4517-4526
Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression
MicroRNAs (miRNAs) have an important role in a wide range of physiological and pathological processes, and their dysregulation has been reported to affect the development and progression of cancers, including hepatocellular carcinoma (HCC). However, in the plethora of dysregulated miRNAs, it is largely unknown which of them have a causative role in the hepatocarcinogenic process. In the present study, we first aimed to determine changes in the expression profile of miRNAs in human HCCs and to compare them with liver tumors generated in a rat model of chemically induced HCC. We found that members of the miR-100 family (miR-100, miR-99a) were downregulated in human HCCs; a similar downregulation was also observed in rat HCCs. Their reduction was paralleled by an increased expression of polo like kinase 1 (PLK1), a target of these miRNAs. The introduction of miR-100 in HCC cells impaired their growth ability and their capability to form colonies in soft agar. Next, we aimed at investigating, in the same animal model, if dysregulation of miR-100 and PLK1 is an early or late event along the multistep process of hepatocarcinogenesis. The obtained results showed that miR-100 downregulation (i) is already evident in very early preneoplastic lesions generated 9 weeks after carcinogenic treatment; (ii) is also observed in adenomas and early HCCs; and (iii) is not simply a marker of proliferating hepatocytes. To our knowledge, this is the first work unveiling the role of a miRNA family along HCC progression.
- 16 January 2012
- Published by Springer Nature in Oncogene
- Vol. 31 (42) , 4517-4526
Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression
MicroRNAs (miRNAs) have an important role in a wide range of physiological and pathological processes, and their dysregulation has been reported to affect the development and progression of cancers, including hepatocellular carcinoma (HCC). However, in the plethora of dysregulated miRNAs, it is largely unknown which of them have a causative role in the hepatocarcinogenic process. In the present study, we first aimed to determine changes in the expression profile of miRNAs in human HCCs and to compare them with liver tumors generated in a rat model of chemically induced HCC. We found that members of the miR-100 family (miR-100, miR-99a) were downregulated in human HCCs; a similar downregulation was also observed in rat HCCs. Their reduction was paralleled by an increased expression of polo like kinase 1 (PLK1), a target of these miRNAs. The introduction of miR-100 in HCC cells impaired their growth ability and their capability to form colonies in soft agar. Next, we aimed at investigating, in the same animal model, if dysregulation of miR-100 and PLK1 is an early or late event along the multistep process of hepatocarcinogenesis. The obtained results showed that miR-100 downregulation (i) is already evident in very early preneoplastic lesions generated 9 weeks after carcinogenic treatment; (ii) is also observed in adenomas and early HCCs; and (iii) is not simply a marker of proliferating hepatocytes. To our knowledge, this is the first work unveiling the role of a miRNA family along HCC progression.
- 31 March 2011
- Published by Elsevier in Journal of Hepatology
- Vol. 54, S91
216 MIR-100 IS DOWNREGULATED FROM EARLY STAGES OF HEPATOCARCINOGENESIS AND CORRELATES WITH OVEREXPRESSION OF ITS TARGET PLK1
- 31 March 2011
- Published by Elsevier in Journal of Hepatology
- Vol. 54, S91
216 MIR-100 IS DOWNREGULATED FROM EARLY STAGES OF HEPATOCARCINOGENESIS AND CORRELATES WITH OVEREXPRESSION OF ITS TARGET PLK1
- 25 February 2009
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 10 (4) , 589-600
Multitarget drugs: the present and the future of cancer therapy
Target therapies for the treatment of human cancers have revolutionized the concept of oncological medicine. This type of therapeutic approach is directed to the inhibition of molecular targets that play a pivotal role in tumor progression -- such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival -- mainly by means of compounds able to block their activity. In the beginning, the aim of target therapies was specifically to hit a single molecule expressed in neoplastic cells. Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease. Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different molecules. This review summarizes the molecular basis of multitarget therapies and the most relevant results obtained in different cancer types.
- 25 February 2009
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 10 (4) , 589-600
Multitarget drugs: the present and the future of cancer therapy
Target therapies for the treatment of human cancers have revolutionized the concept of oncological medicine. This type of therapeutic approach is directed to the inhibition of molecular targets that play a pivotal role in tumor progression -- such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival -- mainly by means of compounds able to block their activity. In the beginning, the aim of target therapies was specifically to hit a single molecule expressed in neoplastic cells. Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease. Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different molecules. This review summarizes the molecular basis of multitarget therapies and the most relevant results obtained in different cancer types.
- 1 February 2008
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 15 (5) , 422-432
From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
Targeted therapies by means of compounds that inhibit a specific target molecule represent a new perspective in the treatment of cancer. In contrast to conventional chemotherapy which acts on all dividing cells generating toxic effects and damage of normal tissues, targeted drugs allow to hit, in a more specific manner, subpopulations of cells directly involved in tumor progression. Molecules controlling cell proliferation and death, such as Tyrosine Kinase Receptors (RTKs) for growth factors, are among the best targets for this type of therapeutic approach. Two classes of compounds targeting RTKs are currently used in clinical practice: monoclonal antibodies and tyrosine kinase inhibitors. The era of targeted therapy began with the approval of Trastuzumab, a monoclonal antibody against HER2, for treatment of metastatic breast cancer, and Imatinib, a small tyrosine kinase inhibitor targeting BCR-Abl, in Chronic Myeloid Leukemia. Despite the initial enthusiasm for the efficacy of these treatments, clinicians had to face soon the problem of relapse, as almost invariably cancer patients developed drug resistance, often due to the activation of alternative RTKs pathways. In this view, the rationale at the basis of targeting drugs is radically shifting. In the past, the main effort was aimed at developing highly specific inhibitors acting on single RTKs. Now, there is a general agreement that molecules interfering simultaneously with multiple RTKs might be more effective than single target agents. With the recent approval by FDA of Sorafenib and Sunitinib - targeting VEGFR, PDGFR, FLT-3 and c-Kit - a different scenario has been emerging, where a new generation of anti-cancer drugs, able to inhibit more than one pathway, would probably play a major role.
- 1 February 2008
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 15 (5) , 422-432
From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
Targeted therapies by means of compounds that inhibit a specific target molecule represent a new perspective in the treatment of cancer. In contrast to conventional chemotherapy which acts on all dividing cells generating toxic effects and damage of normal tissues, targeted drugs allow to hit, in a more specific manner, subpopulations of cells directly involved in tumor progression. Molecules controlling cell proliferation and death, such as Tyrosine Kinase Receptors (RTKs) for growth factors, are among the best targets for this type of therapeutic approach. Two classes of compounds targeting RTKs are currently used in clinical practice: monoclonal antibodies and tyrosine kinase inhibitors. The era of targeted therapy began with the approval of Trastuzumab, a monoclonal antibody against HER2, for treatment of metastatic breast cancer, and Imatinib, a small tyrosine kinase inhibitor targeting BCR-Abl, in Chronic Myeloid Leukemia. Despite the initial enthusiasm for the efficacy of these treatments, clinicians had to face soon the problem of relapse, as almost invariably cancer patients developed drug resistance, often due to the activation of alternative RTKs pathways. In this view, the rationale at the basis of targeting drugs is radically shifting. In the past, the main effort was aimed at developing highly specific inhibitors acting on single RTKs. Now, there is a general agreement that molecules interfering simultaneously with multiple RTKs might be more effective than single target agents. With the recent approval by FDA of Sorafenib and Sunitinib - targeting VEGFR, PDGFR, FLT-3 and c-Kit - a different scenario has been emerging, where a new generation of anti-cancer drugs, able to inhibit more than one pathway, would probably play a major role.